2 articles · Updated · The New York Times · Jul 29
Summary
Inflammasome Therapeutics has two anti-inflammatory drugs in clinical trials—one for a form of macular degeneration and one for ALS—with co-founder Jayakrishna Ambati saying they could reach patients within 18 to 24 months.
The programs target inflammasomes, inflammatory protein complexes increasingly linked to disease; related HIV drugs known as NRTIs have already been shown to lower risks of Alzheimer’s and macular degeneration by blocking that pathway.
That push comes as broader inflammation research gains momentum: GLP-1 drugs such as Wegovy have shown benefits beyond weight loss, including a 20% reduction in cardiovascular death risk that researchers say is only partly explained by weight change.
Researchers are also moving toward real-time inflammation tracking, with Northwestern planning pilot monitors next year that would measure 4 or 5 inflammatory proteins, potentially widening prevention and treatment options across age-related diseases.
Will upcoming wearable monitors that track inflammation in real-time finally allow us to prevent chronic diseases before the first symptoms even appear?
If inflammation drives aging and disease, could a single targeted immune therapy eventually replace dozens of specialized medications for chronic illnesses?
Why do some Indigenous populations have high inflammation without developing chronic diseases, while identical markers in industrialized nations lead to severe illness?
Dual Inflammasome Inhibitors K8 and K9: Clinical Breakthroughs, Safety, and Commercialization Roadmap (2024–2026)
Overview
Inflammasome Therapeutics is advancing its Kamuvudine platform with K8 and K9, two dual-inflammasome inhibitors designed to treat serious eye and neurodegenerative diseases. K8, delivered as a small-molecule, bioerodible implant, showed strong Phase 2 results in 2026 by significantly slowing geographic atrophy progression and improving vision, with no major safety concerns. Kamuvudines are engineered to avoid the toxicities of traditional NRTIs, offering high safety and effectiveness by blocking key inflammatory pathways. K9, an oral tablet, easily crosses the blood-brain barrier and is being tested for diseases like Alzheimer’s and ALS, showing promising early results. Both therapies are designed for easy administration and global accessibility.